retatrutide type 2 diabetes trial results Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 VisualAbstract: Retatrutide reduces body weight

Review peptide safety considerations for additional management strategies

Individuals who stopped using GLP-1RAs were categorized into interruption and discontinuation groups

A new oral GLP-1 therapy, orforglipron (Foundayo) by Eli Lilly and Company, has received US FDA approval, marking a major step forward in accessible weight-management solutions and intensifying competition with Novo Nordisk

Early clinical literature suggests subdermal bipolar radiofrequency is a safe and low risk option for aesthetic management

While the GLP-1RA drugs have traditionally been used in type 2 diabetics, their ability to cause weight loss has captured the minds and imaginations of patients, providers, and drug manufacturers alike

Muchas personas llegan a consulta porque sienten que hacen dieta, intentan cuidarse, pero el hambre, los antojos o la ansiedad por comer hacen que sea muy difcil mantener los resultados